SUCCESS RATE OF UNDESCENDED TESTICLE TREATMENT WITH HUMAN CHORIONIC GONADOTROPIN
Abstract
Introduction: Cryptorchidism is a disorder of the testicles, when during a physical exam,
testicles, one or both of them, are not found in the scrotum, but are found either along the
inguinal canal or in the abdomen. Two main modalities of treatment are hormonal and sur-
gical treatment.
Aim: The aim of this paper was to determine the success rate of hormonal therapy with human
chorionic gonadotropin (hCG) in undescended testicle treatment in patients treated at the
Institute for Child and Youth Health Care in Vojvodina, from January 1, 2010, to December
31, 2017.
Material and methods: This research included the patients from the Institute for Child and
Youth Health Care in Vojvodina ages 0-18, treated from January 1, 2010, to December 31,
2017. Medical documentation has been analyzed and interpreted using methods of descrip-
tive statistic. The research included boys with undescended testicles, to whom the hormonal
therapy was indicated. Patients were divided into 3 groups (<2 years, 2-6 years, >6 years). The
therapy was applied twice a week, in the course of 5 weeks (hCG 250-1000 IJ/dose). The po-
sition 12 months after therapy was used as a final position.
Results: The hormonal descend was achieved in 63 patients (62.4%) of the total number of
patients. Тhe highest success rate was achieved in oldest of our patients (80%).
Conclusion: Hormonal therapy with hCG leads to descent in a high percentage, with very
little transitory adverse effects, and it is an important modality in undescended testicles
treatment.
References
Kucharski P, Niedzielski J. Neoadjuvant human Chorionic Gonadotropin (hCG) therapy may improve the position of undescended testis:a preliminary report. Cent Eur J Urol 2013;66 :224-8.
Kuiri-Hanninen, Sankilampi U, Dunkel L. Activation of the Hypothalamic-Pituitary-Gonadal Axis in Infancy; Minipuberty. Horm Res Paediatr 2014;82:73-80.
Kliegman R, Stanton B, St Geme J, Schor N, Behrman R. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier; 2016. 2592 p
Radmayr C, Dogan HS, Hoebeke P, Kocvara R, Nijman R, Stein R et al. Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. J Pediatr Urol 2016;12:335-43.
Metin A, Kayigil O, Iftekhar Ahmed S. The efficacyof human chorionic gonadotropin in retractile testis. Neuroendocrinol Lett 2005;26(1):39-42.
Bukowski TP, Sedberry S, Richardson B. Is human chorionic gonadotropin useful for identifying and treating nonpalpable testis? J Urol 2001;165(1):221-3.
Ritzén EM. Undescended testes: a consensus on management. Eur J Endocrinol 2008;159(Suppl 1):S87–90.
Dunkel L, Taskinen S, Hovatta O, Tilly JL, Wikström S. Germ cell apoptosis after treatment of cryptorchidism with human chorionic gonadotropin is associated with impaired reproductive function in the adult. J Clin Invest 1997;100:2341–6.
Ludwikowski B, Gonzalez R. The controversy regarding the need for hormonal treatment in boys with unilateral cryptorchidism goes on: a review of the literature. Eur J Pediatr 2013;172:5–8.
Pinczowski D, McLaughlin JK, Lackgren G, Adami HO, Persson I. Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia. J Urol 1991; 146(5):1291-4.
Comploj E, Pycha A. Diagnosis and management of cryptorchidism. Eur Urol Suppl 2012;11:8.
Esposito C, De Lucia A, Palmieri A, Centonze A,Damiano R, Savanelli A, et al. Comparison of five different hormonal treatment protocols for children with cryptorchidism. Scand J Urol Nephrol 2003;37(3):246-9.
Metin A, Kayigil O, Iftekhar Ahmed S. The efficacy of human chorionic gonadotropin in retractile testis. Neuroendocrinol Lett 2005;26(1):39-42